MX2007004425A - Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. - Google Patents
Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.Info
- Publication number
- MX2007004425A MX2007004425A MX2007004425A MX2007004425A MX2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A MX 2007004425 A MX2007004425 A MX 2007004425A
- Authority
- MX
- Mexico
- Prior art keywords
- solvent
- atorvastatin hemi
- amorphous atorvastatin
- dissolving
- calcium
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title abstract 4
- 239000003960 organic solvent Substances 0.000 title abstract 2
- 239000002904 solvent Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 150000002576 ketones Chemical class 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 238000001704 evaporation Methods 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 239000010409 thin film Substances 0.000 abstract 1
- 238000007738 vacuum evaporation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan procesos novedosos para la preparacion de sal de hemi-calcio de atorvastatina amorfa, que comprenden disolver la sal de hemi-calcio de atorvastatina en ciertos solventes organicos y remover el solvente por ejemplo mediante secado por aspersion, evaporacion al vacio rapida, y/o evaporacion de pelicula delgada. Las realizaciones preferidas de estos procesos para preparar la sal de hemi-calcio de atorvastatina amorfa son reproducibles, aplicables a gran escala y no incluyen el uso de hidrocarburos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62002204P | 2004-10-18 | 2004-10-18 | |
PCT/US2005/037751 WO2006045018A1 (en) | 2004-10-18 | 2005-10-18 | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007004425A true MX2007004425A (es) | 2007-06-07 |
Family
ID=35709256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007004425A MX2007004425A (es) | 2004-10-18 | 2005-10-18 | Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060106230A1 (es) |
EP (1) | EP1716114A1 (es) |
JP (1) | JP2007515430A (es) |
KR (2) | KR20070054730A (es) |
CN (1) | CN101039906A (es) |
CA (1) | CA2582087A1 (es) |
DE (1) | DE05810535T1 (es) |
ES (1) | ES2272206T1 (es) |
IL (1) | IL182068A0 (es) |
MX (1) | MX2007004425A (es) |
TW (2) | TW200630335A (es) |
WO (1) | WO2006045018A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CN100406438C (zh) * | 2006-06-30 | 2008-07-30 | 浙江新东港药业股份有限公司 | 一种无定型阿伐他汀钙的制备方法 |
KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
US10189957B2 (en) * | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
CN101538237B (zh) * | 2008-05-30 | 2011-04-06 | 天津和美生物技术有限公司 | 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用 |
KR101050722B1 (ko) * | 2008-12-02 | 2011-07-21 | 대웅바이오 주식회사 | 무정형 아토르바스타틴 칼슘염의 제조방법 |
WO2017106130A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Process for preparing pharmaceutical compositions |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
WO1997003959A1 (en) | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
IN191236B (es) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
IN191496B (es) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
US6646133B1 (en) * | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
CN1423634A (zh) | 1999-11-17 | 2003-06-11 | 特瓦制药工业有限公司 | 阿托伐他汀钙的多晶型物 |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
SK6592003A3 (en) * | 2000-11-03 | 2004-01-08 | Teva Pharma | Atorvastatin hemi-calcium form VII |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
CA2479005C (en) * | 2002-03-18 | 2012-05-22 | Biocon Limited | Amorphous atorvastatin calcium or pravastatin sodium hmg-coa reductase inhibitors of desired particle size |
AU2002356423A1 (en) | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
US20040242670A1 (en) * | 2003-06-02 | 2004-12-02 | Sonny Sebastian | Process for preparation of amorphous atorvastatin calcium |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
CA2465693A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
AU2003247327A1 (en) * | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
CA2562844A1 (en) * | 2004-04-16 | 2005-10-27 | Pfizer Products Inc. | Process for forming amorphous atorvastatin calcium |
CA2578722C (en) * | 2004-08-27 | 2010-02-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
US20070105817A1 (en) * | 2005-11-09 | 2007-05-10 | Jim Page | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
-
2005
- 2005-10-18 US US11/253,770 patent/US20060106230A1/en not_active Abandoned
- 2005-10-18 DE DE05810535T patent/DE05810535T1/de active Pending
- 2005-10-18 KR KR1020077008885A patent/KR20070054730A/ko active Search and Examination
- 2005-10-18 CN CNA2005800353623A patent/CN101039906A/zh active Pending
- 2005-10-18 ES ES05810535T patent/ES2272206T1/es active Pending
- 2005-10-18 TW TW094136357A patent/TW200630335A/zh unknown
- 2005-10-18 CA CA002582087A patent/CA2582087A1/en not_active Abandoned
- 2005-10-18 TW TW098122467A patent/TW200942516A/zh unknown
- 2005-10-18 EP EP05810535A patent/EP1716114A1/en not_active Withdrawn
- 2005-10-18 KR KR1020097005334A patent/KR20090033405A/ko not_active Application Discontinuation
- 2005-10-18 MX MX2007004425A patent/MX2007004425A/es unknown
- 2005-10-18 JP JP2006545622A patent/JP2007515430A/ja active Pending
- 2005-10-18 WO PCT/US2005/037751 patent/WO2006045018A1/en active Application Filing
-
2007
- 2007-03-20 IL IL182068A patent/IL182068A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101039906A (zh) | 2007-09-19 |
EP1716114A1 (en) | 2006-11-02 |
TW200630335A (en) | 2006-09-01 |
TW200942516A (en) | 2009-10-16 |
KR20070054730A (ko) | 2007-05-29 |
DE05810535T1 (de) | 2007-04-19 |
WO2006045018A1 (en) | 2006-04-27 |
JP2007515430A (ja) | 2007-06-14 |
KR20090033405A (ko) | 2009-04-02 |
CA2582087A1 (en) | 2006-04-27 |
US20060106230A1 (en) | 2006-05-18 |
ES2272206T1 (es) | 2007-05-01 |
IL182068A0 (en) | 2007-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007004425A (es) | Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. | |
RU2247113C2 (ru) | Способ получения аморфного аторвастатина | |
WO2008092057A3 (en) | Formulation process method to produce spray dried products | |
MY142016A (en) | Antireflective compositions for photoresists | |
WO2008067215A3 (en) | Vials and apparatus for obtaining an aliquot of a sample | |
UA87492C2 (en) | Regiospecific synthesis of rapamycin 42-ester derivatives | |
DE60041704D1 (de) | Ungen | |
MX2009010688A (es) | Metodo para remover color del material polimerico. | |
WO2009084023A3 (en) | Amorphous ramelteon and process for the preparation thereof | |
ES2524585T3 (es) | Sistema catalizador para la polimerización de olefinas, su producción y su uso | |
EP1550853A4 (en) | BIOCHEMICAL CONTAINER | |
DE602005020717D1 (de) | Verfahren zur Beschichtung von nanostrukturierte Elektroden | |
AR044659A1 (es) | Procedimiento para la formacion de atorvastatina amorfa | |
WO2009011844A8 (en) | Processes for solifenacin preparation | |
ATE495166T1 (de) | Verbessertes verfahren zur zubereitung von rabeprazol-natrium | |
CN103245717A (zh) | 高压成型基质薄膜辅助-激光解析离解质谱定量分析方法 | |
CA2479005A1 (en) | Amorphous atorvastatin calcium or pravastatin sodium hmg-coa reductase inhibitors of desired particle size | |
WO2007017244A3 (en) | A PROCESS FOR THE PURIFICATION OF SUBSTITUTED 2-(2-PYRIDYLMETHYL)SULFINYL-lH-BENZIMIDAZOLE COMPOUNDS BY PRECIPITATION IN THE PRESENCE OF A QUATERNARY AMMONIUM SALT | |
AU2003233064A1 (en) | Process for the preparation of the amorphous form of atorvastatin calcium salt | |
AR048756A1 (es) | Procedimiento para formar atorvastatina amorfa | |
FR2950736B1 (fr) | Revetements photovoltaiques organiques de morphologie controlee | |
WO2008156080A1 (ja) | 質量分析用プレートとそれを用いた薄層クロマトグラフィ-質量分析方法及び装置 | |
DE60232006D1 (de) | Rückgewinnung und recycling chiraler weinsäureverbindungen zur racematspaltung | |
IL155545A (en) | Solvate form of cabergoline | |
BR0309622A (pt) | Composições aquosas lìquidas de derivados de ciclodextrina reativos e um processo de acabamento que usa a referida composição |